Samsung Bioepis Reports 13% YoY Increase in 3Q European Sales of Autoimmune Disease Treatments

'Benepali' Becomes Market Leader in Europe, Surpassing Original Pharmaceuticals

[Asia Economy Reporter Seo So-jeong] Samsung Bioepis (CEO Go Han-seung) reported a 13% increase in product sales in the European region for three autoimmune disease treatments in the third quarter compared to the same period last year.

Biogen, Samsung Bioepis's marketing partner in Europe, announced on the 21st (U.S. local time) in its third-quarter earnings report that the third-quarter European market sales of three autoimmune disease treatment biosimilars (biopharmaceutical generics) developed by Samsung Bioepis (Benepali, Imraldi, Flixabi) reached $207.9 million (2.43 trillion KRW), a 13% increase from $183.6 million recorded in the same period last year.

In particular, Benepali (Enbrel biosimilar), which surpassed cumulative product sales of 2 trillion KRW, achieved the number one market share in the entire European market, surpassing the original drug.

Benepali's third-quarter product sales were $124.2 million (145 billion KRW), a 7% increase compared to the same period last year.

According to pharmaceutical market distribution data compiled by IQVIA, based on sales volume in July, Benepali achieved first place in the entire European market with a 44% market share, surpassing the original drug.

Benepali surpassed the original drug's market share in the EU5 countries (Germany, United Kingdom, France, Italy, Spain) from the second quarter of last year, but this is the first time it has taken first place in the entire European market.

Benepali achieved $100 million in sales in its first year of launch, and cumulative market sales reached $1.8067 billion (2.1 trillion KRW) through the third quarter of this year.

Flixabi (Remicade biosimilar), Samsung Bioepis's second product launched in Europe, achieved sales of $27.5 million (32 billion KRW) in the third quarter, a 49% increase compared to the same period last year.

Imraldi (Humira biosimilar), competing with five products including the original drug, recorded sales of $56.2 million (6.6 billion KRW) in the third quarter, a 14% increase compared to the same period last year.

A Samsung Bioepis official stated, "Despite various external environments in the European region, including the novel coronavirus infection, product sales performance continues to expand steadily," adding, "We will strengthen a stable product supply system so that patients can receive timely prescriptions and strive for continuous sales growth in the European market."

This content was produced with the assistance of AI translation services.